ASTH vs MD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

ASTH

49.7
AI Score
VS
ASTH Wins

MD

41.3
AI Score

Investment Advisor Scores

ASTH

50score
Recommendation
HOLD

MD

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ASTH MD Winner
Net Income 24.00M 69.42M MD
Operating Income 78.53M 98.58M MD
ROE 3.1% 7.9% MD
ROA 1.1% 3.3% MD
Total Assets 2.22B 2.13B ASTH
Cash 429.47M 288.88M ASTH
Debt/Equity 1.27 0.69 MD
Current Ratio 1.40 1.32 ASTH

Relative Price Performance (Last 90 Days)

ASTH 1M: +6.4% · 3M: -8.9% MD 1M: +6.6% · 3M: +9.9%

Current Technical Phase

ASTH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.7 · Price: $37.35

MD

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 66

RSI (14): 66.2 · Price: $28.10

Fundamentals Snapshot

Metric ASTH MD
Market Cap — —
Forward P/E 10.3 11.5
Trailing P/E 46.5 13.1
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.1% 0.3%
Operating Margin 0.0% 0.1%
EPS 0.83 2.15
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ASTH is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.